denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Introduction: Cyclophosphamide, bortezomib and Dexamethasone (CyBorD) has become the standard frontline approach for the treatment of multiple myeloma (MM) in many centers across Canada. In the non-transplant eligible setting, recently a randomized controlled trial reported on the impact of Lenalidomide and Dexamethasone (LD), showing that this doublet-therapy is a feasible and efficacious combination. Based on the above-mentioned success of the LD combination, we aimed to compare the effect of CyBorD and LD for the treatment of non-transplant eligible MM (NTE) patients in the Alberta Myeloma and Dysproteinemia Program (AMDP).
Patients and Methods: The primary objective was to assess ORR and PFS for NTE MM patients treated with CyBorD and LD. The recommended CyBorD regimen was as follows: bortezomib 1.3-1.5 mg/m2 SC or IV days 1, 8, 15 of a 28 day cycle (as of August, 2013 we adopted the a strategy whereby bortezomib can also be given on day 22), cyclophosphamide 300 mg/m2 PO days 1, 8, 15 and 22 and dexamethasone 20-40 mg PO days 1, 8, 15 and 22 with an aim to deliver a minimum of 9 cycles of treatment. LD was given at 25 mg days 1-21 of a 28-day cycle with Dexamethasone 20-40 mg PO days 1, 8, 15 and 22. Dose adjustments were at the discretion of the treating physician. Two-sided Fisher exact test was used to test for differences between categorical variables. A p value of <0.05 was considered significant and survival curves were constructed according to the Kaplan-Meier method and compared using the log rank test.
Results: Ninety-one patients have received CyBorD and 56 have received LD. Clinical characteristics are shown in Table 1. At the time of analysis, 64 and 32 patients in the CyBorD and LD are alive of which 10 and 11, respectively, have progressed, ORR and VGPR rates were 85.7% and 56% for patients treated with CyBorD, and 83.9% and 64% for LD respectively (p=0.3). Estimated median OS was 40 months for CyBorD compared to 66 months for LD (p=0.156). In addition, median PFS was longer for LD patients compared to CyBorD (26 months vs 16.4 months, p=0.018). The rate of treatment discontinuation was similar between both groups (8.7% vs 10%, p=0.3).
In Conclusion: CyBorD and LD appeared to be effective treatment options for NTE myeloma patients with similar response rates. Recognizing the limitations of a retrospective series, it is interesting to note a longer PFS and a trend towards better PFS in the LD group, however, longer follow-up and prospective validation is still required.
Table 1. Clinical Characteristics
Characteristic |
CyBorD, n=91 |
LD, n=56 |
P value |
Age (median) |
73.9 |
73.6 |
0.2 |
Gender Male Female |
57 (62.6%) 34 (37.4%) |
34 (60.7%) 22 (39.3%) |
0.8 |
B2microglobulin (µmol/L) |
4.9 |
4.89 |
0.4 |
Albumin (g/L) |
35 |
36 |
0.7 |
Stage I Stage II Stage III |
17.7% 35.4% 46.9% |
23.5% 37.2% 39.3% |
0.6 |
BMPC (%) |
32 |
37.5 |
0.6 |
Heavy chain: IgG IgA FLC only IgD IgM Biclonal |
50 10 18 1 1 3 |
26 17 9 0 1 0 |
0.068 |
Response rate ORR CR/nCR VGPR PR |
85.7% 23% 31.8% 30.7 |
83.9% 28% 37.5% 17.8% |
0.3 |
Ab: BMPC: Bone marrow plasma cell
Figure 1. Overall Survival according to treatment regimen
Figure 2. Progression-Free survival according to treatment regimen
Disclosures: Jimenez-Zepeda: Celgene: Honoraria ; Amgen: Honoraria ; J&J: Honoraria . Venner: J&J: Honoraria , Research Funding ; Celgene: Honoraria , Research Funding ; Amgen: Honoraria . Sandhu: Janssen: Consultancy , Honoraria ; Celgene: Consultancy , Honoraria ; Novartis: Consultancy , Honoraria ; Amgen: Consultancy , Honoraria . Duggan: Celgene: Honoraria ; Jansen: Honoraria . Neri: Celgene: Research Funding . Bahlis: Johnson & Johnson: Speakers Bureau ; Johnson & Johnson: Research Funding ; Amgen: Consultancy ; Johnson & Johnson: Consultancy ; Celgene: Consultancy , Honoraria , Research Funding , Speakers Bureau .
See more of: Myeloma: Therapy, excluding Transplantation
See more of: Oral and Poster Abstracts
*signifies non-member of ASH